Getting the most out of your first-in-human studies

Anyone engaged in early-stage clinical trials might like to tune in to an upcoming webinar I'll be hosting on first-in-human studies. A lineup of experienced trial experts will be providing a case-study approach to getting the most out of these trials, offering suggestions on expanding the range of safety and efficacy data you can look for on the most efficient basis possible.

We'll be hearing from William Westlin, Ph.D., VP of preclinical research for Avila Therapeutics, who will explore the two Phase Ia trials recently concluded for AVL-292, a promising covalent treatment for hematological malignancies. Nicholas Moore, Ph.D., the director of development and pharmacology at AMRI, will review a recent study on an MCH1 antagonist, discussing the trial design and the process of selecting the candidate while highlighting the pros and cons of moving away from a simple Phase I FIM study design. And Dr. Stephen Flach, MD, executive medical director, clinical pharmacology at Covance, will discuss lessons learned from a broad range of FIH studies undertaken by the CRO.

The webinar will take place on Wednesday, October 5 at 2 p.m. EST. I hope to see you in the virtual audience. You can register here. - John Carroll, editor-in-chief, Fierce Life Sciences. (twitter | email)

Suggested Articles

Moderna’s shares shrunk by nearly 5% before the long holiday weekend Thursday after a report out by Stat said the biotech was delaying its trial.

Keep your post-pandemic trials on track: learn how the right clinical supply chain partner can help sponsors avoid trial disruption. Read now>>

Helsinn Group and MEI Pharma penned a near $500 million biobucks pact for experimental blood cancer drug pracinostat back in 2016.